ENGOT, shared on LinkedIn:
“ENGOT-en15/MITO/GOG-3064/MK-3475-C93 (KEYNOTE-C93) will be featured during Presidential Symposium III at ESMO Congress 2026!
This randomized, open-label Phase 3, ENGOT model C trial compares first-line pembrolizumab with carboplatin plus paclitaxel in patients with mismatch repair-deficient (dMMR) advanced or recurrent endometrial carcinoma.
The trial is being led by The GOG Foundation, Inc, with MITO leading the participating ENGOT groups.
- Presenter: Brian Slomovitz
- Monday 26 October, 17:42–17:54
- Alicante Auditorium, Hall 6
- LBA12
Explore the full ESMO 2026 program”
Brian Slomovitz, Deputy Director at Braman Comprehensive Cancer Center at Mount Sinai Medical Center, added:
“It is such a privilege to be able to work closely with my amazing colleagues from ENGOT.
Together with The GOG Foundation, Inc we are changing the standard of care to improve outcomes for our patients that suffer from these horrible cancers.
Congrats Domenica Lorusso for leading the practice changing Trofuse – 005 study for patients with recurrent endometrial cancer.
It is a great week at ESMO – European Society for Medical Oncology for our patients.”
Title: Study of (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma
Authors: Brian M. Slomovitz, David Cibula, Tayup Simsek, Mansoor Raza Mirza, Beata Maćkowiak-Matejczk, Emma Hudson, Ignacio Romero, Nicoletta Colombo, Jacob Korach, Rutie Yin, Lucy Gilbert, Kosei Hasegawa, Alexandra Tyulyandina, Sally E. Baron-Hay, Lyndsay Willmott, Floor Jenniskens Backes, Robert J. Orlowski, Xuan Zhou, Vivek Khemka, Sandro Pignata
Read the full article:
You may also be interested in:
